Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Alzheimer’s Disease Diagnostic Market Between 2025 And 2029?
The alzheimer’s disease diagnostic market has experienced substantial growth in its size over recent years. It is projected to expand from $6.56 billion in 2024 to $7.26 billion in 2025, achieving a compound annual growth rate (CAGR) of 10.7%. The expansion observed during the historic period can be attributed to several factors: the increasing prevalence of Alzheimer’s disease and dementia, a heightened recognition of the significance of early diagnosis for more effective management, technological advancements in imaging methods such as MRI and PET scans, a rise in investment toward research and development concerning neurodegenerative diseases, and government-led initiatives and funding for Alzheimer’s research and diagnostics.
The market for Alzheimer’s disease diagnostics is projected to experience swift expansion over the coming years, set to reach $10.81 billion by 2029 with a compound annual growth rate (CAGR) of 10.5%. This growth in the forecast period can be attributed to the creation of blood-based biomarkers for non-invasive diagnosis, increasing demand for personalized medicine and precise diagnostics, the integration of AI and machine learning into diagnostic instruments for early identification, the expanding use of digital health technologies for remote observation and diagnosis, and the enhancement of healthcare infrastructure in developing markets to boost accessibility. Major trends anticipated during this period include the rise of multi-modal diagnostic strategies that blend imaging, biomarkers, and cognitive assessments; a greater emphasis on point-of-care diagnostic options for quicker outcomes; the development of wearable devices for ongoing cognitive health tracking; increased partnerships between biotechnology firms and research bodies for novel solutions; and an expansion in direct-to-consumer genetic testing for evaluating Alzheimer’s risk.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp
Which Drivers Are Supporting Growth Of The Alzheimer’s Disease Diagnostic Market?
The expanding prevalence of chronic disease is anticipated to fuel the expansion of the alzheimer’s disease diagnostic market moving forward. A chronic disease is defined as a persistent health condition lasting beyond three months, and its rise is attributed to a combination of interconnected elements such as lifestyle choices, environmental factors, genetic predispositions, and socioeconomic circumstances. The existence of chronic conditions like cardiovascular difficulties, diabetes, and hypertension elevates the likelihood of developing Alzheimer’s disease (AD) and other dementias. For example, a January 2022 report by the American Heart Association Inc., a US-based nonprofit, projected that brain disorders in the US would climb to 9.3 million by 2060, with current figures already increasing in the US, and globally, one in every six individuals is affected by a brain disease. By 2021, an estimated 1 billion people worldwide were projected to suffer from brain disorders. Consequently, the increasing burden of chronic disease will propel the growth of the alzheimer’s disease diagnostic market.
What Are The Different Segment Classifications Within The Alzheimer’s Disease Diagnostic Market?
The alzheimer’s disease diagnosticmarket covered in this report is segmented –
1) By Type: Triage; Diagnosis; Screening
2) By Diagnostic Technique: Biomarkers; Imaging Techniques; Genetic Testing; Cognitive Assessment Tests
3) By End User: Clinics; Hospitals; Diagnostic Centers; Pharmaceutical Companies; Academic Research Center
Subsegments:
1) By Triage: Cognitive Testing; Imaging Techniques
2) By Diagnosis: Biomarker Testing; Neuroimaging
3) By Screening: Neuropsychological Testing; Genetic Testing
How Are Emerging Market Trends Shaping The Alzheimer’s Disease Diagnostic Industry Landscape?
Leading companies in the alzheimer’s disease diagnostic market are prioritizing the development of advanced blood-based biomarker tests, aiming to streamline the diagnostic process for Alzheimer’s disease, reduce reliance on more invasive procedures, and improve timely treatment access for patients. For instance, in October 2023, Quanterix, a US-based biotechnology research company, launched the LucentAD p-Tau 217 test, a biomarker for Alzheimer’s pathology that offers clinical sensitivity and specificity when detected in blood. Traditional methods for cerebrospinal fluid (CSF) biomarkers, including positron emission tomography (PET) or lumbar puncture, are expensive, invasive, and not broadly accessible. This new test also combines Quanterix’s ultra-sensitive SimoaÒ technology with J&J Innovative Medicine’s thoroughly validated p-Tau 217 antibodies, resulting in excellent accuracy and a simpler process.
Who Are The Key Multinational Companies Dominating The Alzheimer’s Disease Diagnostic Market?
Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report
Which Regional Markets Are Contributing Most To The Alzheimer’s Disease Diagnostic Industry Expansion?
North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Alzheimer’s Disease Diagnostic Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp
Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2025, By The Business Research Company
Hematology Diagnostic Devices And Equipment Global Market Report 2025
Immunochemistry Diagnostic Devices And Equipment Global Market Report 2025
Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model